Catalyst Wire Dossier Catalyst Wire Dossier

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide

· Gilead Sciences
Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide, covering 2018-02-22 to 2020-02-05. Get the full timeline:

Most recent: Clinical Trial Update: A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study [Phase 4]

See pricing